Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

28.84USD
20 Apr 2018
Change (% chg)

$-0.05 (-0.17%)
Prev Close
$28.89
Open
$28.93
Day's High
$29.14
Day's Low
$28.83
Volume
2,118,566
Avg. Vol
1,990,455
52-wk High
$29.92
52-wk Low
$24.54

Latest Key Developments (Source: Significant Developments)

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

Boston Scientific Announces Acquisition Of NVision Medical Corp
Monday, 16 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES ACQUISITION OF NVISION MEDICAL CORPORATION.BOSTON SCIENTIFIC-DEAL CONSISTS OF CASH PAYMENT OF $150 MILLION, AND UP TO ADDITIONAL $125 MILLION IN POTENTIAL CLINICAL & COMMERCIAL MILESTONES OVER 4 YEARS.BOSTON SCIENTIFIC CORP - ACQUISITION IS EXPECTED TO BE IMMATERIAL ON AN ADJUSTED BASIS IN 2018 AND 2019.BOSTON SCIENTIFIC CORP - ACQUISITION IS EXPECTED TO BE DILUTIVE ON A GAAP BASIS THROUGH 2020 AND LESS ACCRETIVE THEREAFTER DUE TO COSTS.BOSTON SCIENTIFIC CORP - ACQUISITION IS EXPECTED TO BE ACCRETIVE ON AN ADJUSTED BASIS AFTER 2018 AND 2019.  Full Article

Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM.  Full Article

Boston Scientific Announces Preliminary Unaudited Sales For Q4 and FY17
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017.Q4 SALES $2.41 BILLION VERSUS I/B/E/S VIEW $2.35 BILLION.  Full Article

Boston Scientific Receives FDA Approval For Vercise Deep Brain Stimulation System
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VERCISE™ DEEP BRAIN STIMULATION SYSTEM.BOSTON SCIENTIFIC CORP - DATA FROM INTREPID STUDY OF DBS SYSTEM IS EXPECTED TO BE RELEASED IN 2018.  Full Article

Appaloosa LP cuts share stake in BofA, dissolves share stake in Wells Fargo and Activision Blizzard
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - APPALOOSA LP:Appaloosa LP dissolves share stake in Activision Blizzard Inc - SEC filing.Appaloosa LP cuts share stake in Bank Of America Corp by about 28 percent to 6.3 million shares.Appaloosa LP raises share stake in Boston Scientific Corp by about 66 percent to 3.8 million shares.Appaloosa LP dissolves share stake in L Brands Inc.Appaloosa LP dissolves share stake in Wells Fargo.Appaloosa LP cuts share stake in Dollar General Corp by 36 percent to 599,264 shares.Appaloosa LP raises share stake in NRG Energy Inc to 8.4 million shares from 1.3 million shares.Appaloosa LP - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.Source text for quarter ended Sept 30, 2017 (http://bit.ly/2zJRjl2).Source text for quarter ended June 30, 2017: (http://bit.ly/2uWm5mq).  Full Article

Boston Scientific announces results for third quarter 2017
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Boston Scientific Corp :Boston Scientific announces results for third quarter 2017.Q3 GAAP earnings per share $0.20.Sees FY 2017 revenue $8.985 billion to $9.015 billion.Q3 sales $2.222 billion versus I/B/E/S view $2.21 billion.Sees Q4 2017 GAAP earnings per share $0.19 to $0.23.Sees FY 2017 GAAP earnings per share $0.71 to $0.75.Q3 adjusted earnings per share $0.31.Sees Q4 2017 sales $2.345 billion to $2.375 billion.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Boston Scientific Corp qtrly Cardiac Rhythm Management sales of $‍​463 million versus $467 million.Boston Scientific Corp qtrly interventional cardiology sales of $589 million versus $568 million.Sees Q4 2017 adjusted earnings per share $0.32 to $0.35 excluding items.Q4 earnings per share view $0.34, revenue view $2.33 billion -- Thomson Reuters I/B/E/S.Boston Scientific Corp sees FY 2017 adjusted earnings per share ‍$1.24 to $1.27​ excluding items.Fy2017 earnings per share view $1.25, revenue view $8.95 billion -- Thomson Reuters I/B/E/S.  Full Article

Neovasc and Boston Scientific closes $75 million agreement
Tuesday, 13 Dec 2016 

Neovasc Inc - : On Dec 12, U.S. District court for district of Massachusetts held hearing in connection with co's litigation against cardiaq . Court denied cardiaq's motion for temporary restraining order to prevent deal between neovasc and boston scientific corporation from closing . Court also indicated a willingness to stay enforcement of judgment against neovasc pending appeal .Stay enforcement subject to neovasc posting a partial bond in amount of US$70 million.  Full Article

Boston Scientific's unit Falcon Merger extends offer for all shares of EndoChoice Holdings
Friday, 4 Nov 2016 

Boston Scientific Corp : Says unit, Falcon Merger Corp has extended its previously announced tender offer for all shares of EndoChoice Holdings .Boston Scientific announces extension of the cash tender offer for all shares of EndoChoice.  Full Article

EndoChoice holdings agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances
Tuesday, 27 Sep 2016 

Endochoice Holdings Inc :Agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances.  Full Article